This article first appeared on GuruFocus.
Novo Nordisk (NYSE:NVO), the diabetes-and-obesity drug leader, stayed flat on Thursday morning, with the shares quoted at $44.535, even after China cleared Wegovy for metabolic dysfunction-associated steatohepatitis, or MASH. The authorization makes Wegovy China's first approved GLP-1 receptor agonist for the serious liver condition.
This is another clinical win for semaglutide. Wegovy now reaches beyond weight loss and cardiovascular protection into liver disease, potentially opening another large patient pool. But the commercial details remain blank: Novo provided no Chinese launch date, pricing, reimbursement plan or estimate of additional revenue.
Warning! GuruFocus has detected 4 Warning Sign with NVO.
Is NVO fairly valued? Test your thesis with our free DCF calculator.
Novo generated DKK78.49 billion in second-quarter sales and DKK33.39 billion in adjusted operating profit, producing a powerful 42.5% margin. The valuation picture is striking: the $44.535 share price sits 58.43% below the $107.14 GF Value estimate. Investors clearly want proof that Wegovy's expanding clinical reach can translate into faster growthnot simply another regulatory milestone.